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Introduction
Viruses, bacteria, or fungi, exposure to toxins,
like alcohol or drugs, and autoimmunity are only
few of the several possible etiological factors that
contribute to the hepatocellular damage, character-
izing liver diseases. Particularly, patients infected
by major hepatotropic viruses present a continuous
spectrum of hepatic pathology, from mild chronic
hepatitis to end-stage cirrhosis and hepatocellular
carcinoma. According to the statistical data from
the Italian Ministry of Health, from 1980 to 2003
(the last available data), liver diseases, especially
cirrhosis, have been consistently listed as one of the
top ten fatal diseases (7th position), among the high-
est in Europe and industrialized countries, leading
more than 15,000 fatalities every year(1). On a
worldwide scale, liver cancer, one of the most life-
threatening solid tumours, remains the 5th most fre-
quent cancer, with an incidence of about 560,000
new cases every year, and the 2nd most common
cause of cancer-related deaths(2). Besides, liver dis-
eases are not easily diagnosed, as the liver is able to
keep on its normal activity even if partially dam-
aged. So, there is even more urgent need to diag-
nose liver diseases as soon as possible to prevent
chronic, and often fatal, degeneration of hepatocel-
lular structures. However, medical diagnosis is a
highly demanding task, requiring expert physicians
to analyze and judge various examination frame-
works (i.e. symptoms/signs), as well as laboratory
and radiological findings. Acquiring sufficient
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ABSTRACT
Background e Aims: We investigated if an Artificial Neural Network ANN) is able to identify hepatobiliary disease in selected
patients affected with several, already diagnosed, hepatobiliary diseases, using only clinical and few laboratory findings, to provide
a tool for early and “pre-imaging”(i.e. without using radiologic techniques) diagnosis of patients in real-life context. 
Methods: We used data from medical records of 270 patients affected with several hepatobiliary diseases. Patients were divi-
ded in three groups: Gtrain (with clinical paradigmatic characteristics), to train network; Gtest (“clinically similar” to those of Gtrain)
to test the trained network; and, finally, Gval significantly different from the above sets), to validate ANN diagnostic capabilities.
Results: After training, the network provided right answer 96% of times, while in remaining 4% network outputs were only
partly wrong. Comparing sets Gtrain and Gtest, we deduce that ANN is stable under minor modifications. Considering Gval, right
answer was given 80% of cases, while remaining results were, again, enough correct, an evidence of ANN’s stability under major
modifications.
Conclusions: our ANN works well for patients with known hepatobiliary diseases. Next step will be to use ANN for patients
with suspected hepatobiliary diseases, and to extend our ANN to other human diseases.
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experience and developing substantial expertise
may take several years for a physician. Moreover,
experience and expertise alone do not guarantee
accurate diagnosis. Heavy clinical workload raises
the risk and uncertainty of the medical diagnosis.
For this, the need of auxiliary systems for diagnosis
has become increasingly crucial. 
Since few decades the rapid developments of
information technology helped physicians to avoid
transcribing patient medical histories. Using com-
puter data processing systems, medical histories
and other related information could be efficiently
stored, in great amount, in databases for quick
retrieval and analysis. This late possibility opened
new sceneries, starting with statistical analysis of
groups of patients or using different computer aided
strategies. One of these last, whose potentialities
are not yet fully explored, is provided by the so-
called artificial neural networks (ANNs). ANNs,
originally from neurobiological models, are sys-
tems composed of highly interconnected and inter-
acting simple signal-processing units. Just like
human brain, an ANN can learn by example and
dynamically modify itself to fit and understand the
input data. An ANN should be an innovative tool
for clinical decision-making and have been applied
in several medical research areas, including thyroid
function, myocardial infarction, and cancer diagno-
sis(3-12). Several authors have also used ANNs to ana-
lyze different aspects of liver disease diagnosis.
Particularly, Kim et al.(13) used ANNs to analyze
liver disease risk factors, Nakano et al.(14) to dis-
criminate mild and severe chronic active hepatitis,
Piscaglia et al.(15) to classify significant fibrosis, cir-
rhosis, and other liver diseases, and, finally,
Maiellaro et al.(16) to predict therapy response of
patients with chronic hepatitis C.
The main goal of this study was to investigate
if an ANN is able to identify the kind of (liver or
hepatobiliary) disease in a cohort of selected
patients, affected with several, already diagnosed,
hepatobiliary diseases, using only few clinical and
laboratory findings, in order to provide an useful
tool for physicians for differential diagnosis of their
patients in the real-life clinical context. Stated in
different words, we were interested to build up an
efficient and ‘economic’ network, i.e. a network
which may suggest an high-probability diagnosis to
the doctors without expensive laboratory and radio-
logic tests, guiding them to consider and perform
further diagnostic examinations, i.e. more expen-
sive laboratory, radiologic and invasive tests.
Patients and methods
Clinical data
This study was carried out using a database
accounting data from the medical records of a sam-
ple of 270 patients mean age 52 (18-83) years, 109
females, mean age 51 (19-81) years, and 161 males,
mean age 52 (21-80) affected with several hepato-
biliary diseases, admitted to our Department, during
the period 2002-2010, as outpatients or inpatients.
Diagnosis of hepatobiliary disease was achieved
assessing clinical history, registering symptoms,
physical examination, laboratory and radiologic
findings, and, in some case 34 patients, (12.6% of
total), by liver biopsy and pathology examination.
Data set
Using the medical records of the patients, we
identified 289 relevant variables, corresponding to
symptoms, signs, and abnormalities from biomed-
ical tests. These variables, with the corresponding
reference ranges used in the laboratory of our
Institution, are listed in Tables 1-3. Some of the
considered variables were structured data (e.g.
check boxes in the medical records, which were
crossed out depending on normality or abnormality
of clinical finding, and laboratory results). Others,
on the contrary, were unstructured (e.g. text ele-
ments found in the medical records, especially for
symptoms and signs). We adopted, for each variable
introducing an intrinsic degree of arbitrariness for
unstructured data, a value on a scale 0-10, (corre-
sponding to the presence and to the intensity 0
pointing out absence, 1 to 10 for mild to severe) of
every symptom, sign, and biomedical test abnor-
mality of each single patient. The patients were
divided in three groups, named Gtrain, Gtest and
Gval, the first being used to train the network; the
second, with clinical and laboratory data not very
different from Gtrain, to test the trained ANN, and
the third to further validate the procedure.
However, before training the network, a set of 40
input variables, S, was extracted from the complete
set of 289 inputs, and only these variables were
used to train the (ANN Table 4). 
To uniquely determine which kind of liver dis-
ease affects the patient it would have been natural,
in principle, to consider all the original 289 symp-
toms, signs and laboratory abnormalities, and, using
their values, to deduce the corresponding disease.
However, this is not necessarily the best procedure,
since, for instance, two different sets of these 289
inputs may correspond to the same disease. In other
words, there is not a one-to-one correspondence
between diseases and these complete 289 input
data. The main criterium adopted in choosing S was
to focalize on few symptoms/signs/laboratory tests,
in our view, more predictive of liver disease. A sec-
ond criterium was to avoid, as much as possible,
expensive laboratory tests, in order to economize
patient’s first evaluation. Other symptoms/signs, as
well as expensive tests, would have been consid-
ered at a second stage of the analysis, especially if
the network’s outcome were not enough persuasive.
Thirdly, if a disease can be found only by perform-
ing a certain laboratory test, then this must be
included in S, otherwise, not surprisingly, the net-
work will not be able to recognize this particular
disease i.e. Hepatitis D Virus antigen demonstra-
tion). Finally, two different diseases must corre-
spond to two different input vectors (see below).
This is to prevent the network to confuse the two.
For this reason, S cannot be taken too small. 
ANN analysis and construction
Neural networks have been applied along the
years, in several fields(17,18). An ANN consists of
simple signal-processing units, the so-called “neu-
rons”. Each neuron can have multiple inputs, but it
only has a single output. The input-output relation-
ship is controlled by a transfer function. The inputs
of a neuron are first multiplied by a weighting fac-
tor that determines the extent to which each input
influences the output, then the weighted inputs are
summed to form a pre-neuron sum. This is finally
plugged through the transfer function resulting in
the neuronal output. An artificial network is built up
organizing individual neurons into a series of lay-
ers. In a so-called feed-forward fully-connected net-
work, each neuron gets an input from neurons
located in the preceding layer, generating a single
output result, becoming itself new input variable for
each neuron in the successive layer. The layers
between the first input variables and the final out-
put layer are called “hidden” layers. Assuming to
have fixed the transfer function and the layers
topology, the desired behaviour of an ANN can be
driven by adjusting the neuronal connections. This
is called training the network, and is carried out by
using a data set for which the correct output of the
corresponding input variables is known. This is the
phase during which Gtrain is used. A good network
is obtained when the training process is able to
reduce the output errors for the training set to negli-
gible values. When this is achieved, then the ANN
has properly learned. In other words, after the
learning process, if you give to the network a par-
ticular input data vector, which was already used to
train the network, you should get the same (correct)
result. This is a natural requirement, which, howev-
er, is not automatically satisfied, because of the
very large freedom degrees intrinsic in the defini-
tion of any ANN. The trained ANN can then be
used to estimate the output values for new input
data, e.g. for patients which were not used during
the training procedure, for instance for those in
Gtest. This is the phase called testing the network,
which is essential to check the stability of the ANN
under minor modifications of the inputs. If the per-
formance of the network is not good, i.e. if the out-
puts corresponding to Gtest differ significantly from
the correct known ones, the network should be re-
modelled, changing the number of neurons, the lay-
ers, fixing a different value of the acceptable error,
and so on. This new network should now be trained
again, using Gtrain, and then tested, using Gtest.
Adding neurons or hidden layers to a network does-
n’t mean, necessarily, improving its efficiency, due
to the intrinsic complexity of an ANN, and a more
complex ANN architecture could disperse the
results. Hence, finding the correct number of neu-
rons and of hidden layers to get an efficient ANN is
already a difficult task. The last phase has been
called here validating the network: the patients in
Gval were used to check the concrete ability of the
network to recognize the known diseases. The main
difference with the testing and the training phases
was in the choice of Gval, which included only
those patients of our data set whose related vectors
were significantly different from those in Gtrainand
Gtest. After the training, the testing and the validat-
ing phases, if we give to the network a new vector
of data for which the output in unknown, the net-
work should determine an output value, which
should be interpreted as the disease described by
this vector. This procedure permits to hint a diagno-
sis for new data set, i.e. for other patients with sus-
pected liver diseases. 
Building Gtrain, Gtest and Gval
As stated above, patients were divided in three
groups of 30, 90 and 150 ones, respectively. The
first group, Gtrain, whose patients were chosen
because of their “paradigmatic” characteristics,
according to the international literature, was used to
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train the network. The 90 patients in Gtest, chosen
because of their similarities with those of Gtrain,
were used to test the trained network. The set Gval,
consisting of patients significantly different from
those of the above sets, was finally used to further
validate the diagnostic capabilities of our ANN. The
idea underlying this particular partition of the
patients can be easily understood: once the ANN is
trained, we wanted to check if the network is stable
under minor modifications (i.e. changing a little bit
the inputs does not change much the outputs). This
is important to avoid problems arising from the
uncertainty intrinsic, for instance, in the “text-to-
number” procedure used for unstructured data, gen-
erating the input vectors. Another source of uncer-
tainty is determined by the probability that different
input variables values could correspond to the same
disease. For instance, the numerical value of a
given sign can be different from a patient to the
other, even if they suffer with the same disease.
Furthermore, two different physicians may attribute
two slightly different values to the same sign of a
certain patient. After checking this stability, we
were interested in considering the ANN’s reaction
to major modifications (i.e. to major changes in the
input vectors). 
Using the above-described criteria, we extract-
ed Nsym symptoms out of the ones listed in Table 1,
Nsigns signs out of the ones listed in Table 2, and
Nlab laboratory results out of the ones listed in
Table 3. Hence, S is made of Nsym + Nsigns + Nlab =
NS (quantities =40). Each patient Pj in the training
set Gtrain = ⎨Pj, j = 1, 2, …, Mtrain = 30⎬ does
therefore correspond to an NS-dimensional vector
Xj, where the NS components of Xj are the values of
the corresponding symptoms, signs and laboratory
results, as listed in Table 4. The (known) output,
corresponding to Xj, is a 30-dimensional vector
(one dimension for each disease) Yj, with all zero
entries, except in the j - th position, in which the
vector takes the value one: (Yj)k = δj,k. For testing
purpose, a second group of 90 patients, Gtest = ⎨Pj,
j = 1, 2, …, Mtest = 90⎬, has been considered. Our
testing phase consists in checking whether the
trained network recognize these diseases. In other
words, each Pj belonging to Gtest was described,
again, by a 40-dimensional vector Xj, while the dis-
ease affecting Pj is known, but, in this testing pro-
cedure, should be confirmed by the network. Our
analysis was concluded by a validating phase,
involving a third group of 150 patients, Gval = ⎨Pj,
j = 1, 2, …, Mval = 150⎬. Our validating phase
consists in checking whether the network recognize
the (again, known) disease affecting these other
patients, whose vectors were significantly different
from those describing the ones in the two other
groups. 
The Software
Several possible software to build up efficient-
ly ANNs are available. In this study we have used a
software which has turned out to be very powerful
and convenient for our analysis, EasyNN-plus©, that
can be obtained from the web site www.justnn.com.
This software allows to fix several aspects of the
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Table 1: Symptoms of liver disease (in alphabetic order).
ANN to construct. In particular, it could fix the
number of layers, the number of neurons for each
layer, the learning rate and the error threshold used
to stop the training procedure. The network we used
consisted in one hidden layer made by 40 neurons.
We fixed the learning rate value, and the value 10-5
for the error. The network was trained with a back
propagation algorithm, and the threshold error was
achieved after 2012 epochs, which corresponds,
working with an ordinary laptop, with no particular
calculating power (the one used here has a 2.5MHz
dual core processor, and 3Gb of RAM), to few sec-
onds. The transfer function used in each neuron is a
sigmoidal: f(x) = 1/(1+ex).
Results
ANN results on patients in set Gtest and Gval are
given in Tables 5 and 6, respectively. These are orga-
nized in the following way: the first column lists the
various diseases considered by the ANN; the second
shows the percentage of correct diagnosis, whose
corresponding number is given, together (when
needed) with the uncorrected one, in the third col-
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Table 2: Signs of liver disease (in alphabetic order).
umn.
The other three columns list the outputs pro-
duced by the network in decreasing order of proba-
bility, expressed by a value deduced, looking at the
numerical results of the ANN output vectors: the
larger the output value, the greater the probability
of the corresponding disease. We gave only the first
three choices. For instance, in Table 5, in line 1,
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Table 3: Laboratory findings of liver disease (in alphabetic order) and corresponding reference ranges used in the labo-
ratory of our Institution.
r.r.: reference range
corresponding to “hepatocellular adenoma”, our
network produced three times (i.e. in all the sub-
jected cases), as its first choice diagnosis, the cor-
rect one. The second and third choices were
“autoimmune hepatitis type I” and “liver haeman-
gioma”, respectively. This means a 100% of correct
diagnoses. On the other hand, “biliary tract cancer”,
in line 30, was recognized 2 times out of 3. The
uncorrected diagnosis of the network was “acute
cholangitis” as first choice, even if, however, the
correct diagnosis was the second choice. In some
cases (i.e. line 14, “gallbladder empyema”), many
disease are listed as second or third choice, given
their identical or strictly similar probability values,
or no third choice is listed, since all the other dis-
eases were considered, by the ANN, equally unlike-
ly. Table 6 is organized in the same way. 
Results described in Table 5 were quite inter-
esting: the network provided the right answer (i.e.
the same disease diagnosed by a standard diagnos-
tic approach) 96% of the times, while in the
remaining 4% network outputs were only partly
wrong. First of all, because the correct disease was
the second (never the third) choice. Secondly, and
more important, because network mistakes were not
real ones: with the same kind of information, even a
physician would have done exactly the same set of
choices. Therefore, it seems that the network
worked like a human being, or even better. This
shows that our approach essentially imitates, in a
certain sense, a real physician's behaviour: he does-
n’t estimate errors, or compute standard deviations.
He just considers what he thinks is the most proba-
ble disease. Recalling that the set Gtest is not very
different from Gtrain, the main conclusion of this
first part of our analysis is that our ANN is stable
under minor modifications. 
Table 6 represents results on the patients in set
Gval, which were sufficiently different (from a qual-
itative and, therefore, from a quantitative point of
view) from the ones chosen to train and to test the
network. Looking at this table, we still obtained
acceptable results (i.e. stability under major modifi-
cations). In fact, out of the 150 cases proposed to
the network, 120 (80%) were correctly diagnosed.
It must be noticed also that the remaining (wrong)
results were, again, sufficiently right, i.e. they were
compatible with the information possessed by the
network. 
Summarizing, considering together the sets
Gtest and Gval, the percentage of correct diagnosis
provided by the network was the 86%. 
Discussion
Emerging results from this study suggested
that our ANN was able to predict, with a good accu-
racy, in a set of patients affected with known sever-
al hepatobiliary diseases, the type of hepatobiliary
disease, using only few, minimal, clinical and bio-
chemical variables, as input data, in a efficient, eco-
nomic and pre-imaging procedure. 
Based on the results of this study, the proposed
model can be used as a supporting system in mak-
ing decisions related to hepatobiliary disease diag-
nosis and subsequent treatment. ANN can retrieve
the most similar case from the case database in
order to solve a new hepatobiliary disease problem.
Reducing diagnostic errors, ANN could be an inno-
vative way to early achieve hepatobiliary disease
differential diagnosis. 
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Table 4:Selected input variables (S) used to train the
ANN
It should be stressed that this study did not
want to suggest possible replacement of experi-
enced clinicians by advanced computer-aided deci-
sion systems, but simply to point out that these sys-
tems should be accounted as a potential decision
aid in order to better address investigations, to save
costs, and to better use resources, as already
described in other fields of medical settings. In
752 Pasquale Mansueto, Marcello Cammarata et Al
Table 5:ANN results on the patients in set Gtest
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Table 6: ANN results on the patients in set Gval.
other words, our intention was not to build a net-
work that fully substitutes physicians and their role.
Really, our network basically provides a diagnostic
orientation, a sort of hint for real-life physician, an
aid for differential diagnosis of their patients, with a
high probability of being true (= very close to
definitive diagnosis). The ability of our network
was to orient well, in absence of further laboratory
and radiological investigations, or in economical
restricted conditions, towards a correct diagnosis,
although it is clear the need, even just for forensic
reasons, to perform, for real-life patient, other diag-
nostic and follow-up tests(3-12).
We are aware that the current study has some
limits. First of all, there was a certain freedom in
our “text-to-number” procedure for unstructured
data of patients' medical records, and in assigning a
given number to the various symptoms/signs/labo-
ratory tests for the various patients of the three
groups. Secondly, even if we tried to motivate our
choice, the set S and NS could have been chosen
differently. However, our extraction procedure was
not very different from what any physician really
does during the deduction of a diagnosis, keeping
those information which he assumes to be the most
relevant and neglecting the others. Last but not
least, the results achieved by our ANN were quite
satisfactory: this suggests that our choices were cor-
rect and produce an efficient network.
Moreover, we should also recall that there was
a certain freedom in choosing which patients should
be included in Gtrain, Gtest and Gval. Motivations of
such a choice were argued above, considering the
different characteristics of the three phases of ANN
implementation.
A final comment concerning our ANN is the
following. The network has proved to be efficiently
trained by using a single patient for each disease.
This is an interesting feature of our ANN, which is
probably due to an appropriated choice of the set S.
As results showed, there was absolutely no need to
train the network with more patients for each dis-
ease. Of course, this implies that the training proce-
dure was very fast, while it would surely take more
time when fixing Mtrain >30. Concerning NS, and
the explicit choice of the set S, we had a lot of free-
dom. After some attempts, we fixed NS = 40, and
the related set S. As a matter of fact, adopting this
choice, the ANN produced satisfactory results when
compared with the amount of information given to
the network, and with other possible choices of NS
and S.
In conclusion, the current analysis can be
described as a preliminary study. It will need fur-
ther validation in a separate cohort of patients with
liver diseases. Also, a prospective study that com-
pares the ANN with physician assessment in real
time will be of interest, particularly, if the ANN
diagnosis changes the decision-making process at
the point of care. In addition, it could be interesting
to write a dedicated software to deal with medical
diagnostic-related analysis, also in view of other
possible application fields. In fact, it is clear that a
similar ANN can be organized for different kind of
diseases, so that many possibilities were opened by
our analysis.
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